FeesSafety
Pluang+

XMax launches $30M share buyback program to boost shareholder value.

Company Fundamentals
03 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
XMax launches $30M share buyback program to boost shareholder value.

XMax Inc. announced a $30 million share repurchase program, allowing the company to buy back its common stock at prices below $5.50 per share. The program will start after the company releases its Q3 2026 financial results and will last for three months. This move reflects XMax's confidence in its long-term strategy, balancing growth investments in AI and furniture with shareholder returns. The buyback will be funded from existing cash reserves and managed based on market conditions and company needs.

XMax's $30 million share repurchase program is announced as context for readers. For those following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 03, 2026 19:01 WIB: out of 134 priced US stocks, 43 rose and 80 fell. Notable movers include BALL at USD 66.53 with a 1-day change of -2.26%, BBWI at USD 22.68 with a 1-day change of -2.20% and 100% sell order activity, and DHI at USD 149.60 with a 1-day change of -2.18% and 100% buy order activity.

More News

Automatic FOUP Opener Market to reach $6.04B by 2032 with 5.36% CAGR driven by fab automation and contamination control

Automatic FOUP Opener Market to reach $6.04B by 2032 with 5.36% CAGR driven by fab automation and contamination control

The global Automatic FOUP Opener Market is projected to grow from USD 4.41 billion in 2026 to USD 6.04 billion by 2032, expanding at a CAGR of 5.36%. Growth is driven by increasing fab automation, stricter contamination control requirements, and dema...

Market News
Bullish
20 minutes ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
3 hours ago
Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
3 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
3 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App